Xeloda Market: By Type (500mg and 150mg), By Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Xeloda's market size was poised to grow at 5.7 % CAGR from 2023 to 2029. Xeloda is a brand-name prescription medication used to treat certain forms of cancer in adults. Specifically, Xeloda also known as “Capecitabine” is approved to treat: Metastatic breast cancer. With metastatic breast cancer, breast cancer has spread to other parts of the body. The growth of the Xeloda market rose to the rising cases of cancer worldwide, increasing demand for targeted drugs to lower the massive side effects drive the market. According to the American Cancer Society Report, it is estimated in 2019, there will be 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. Increased deaths encourage key players towards research and development of new products and launches which create major opportunities in the Capecitabine market. lack of trained professionals and high cost of treatment hamper the market growth, which creates hindrances in the treatment. According to WHO, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. Geographically, North America held the major market share in 2022 and is expected to dominate the global embolization market in the forecasted years.

Xeloda Market Key Developments:
  • In December 2022, the FDA approved updated drug labeling including new indications and dosing regimens for Xeloda (capecitabine) tablets, under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. This is the first drug to receive a labeling update under this pilot program.
  • In April 2022, Cheplapharm Arzneimittel GmbH (“Cheplapharm”) signed an agreement with F. Hoffmann-La Roche Ltd. to acquire the worldwide rights to Xeloda® (capecitabine). Under the terms of the agreement, Cheplapharm will receive product rights for Xeloda® in certain countries worldwide including the USA.

Xeloda Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.7%

Largest Market

North America

Fastest Growing Market

North America
Xeloda Market Dynamics

The increasing prevalence of vascular diseases across the world is the major market driver in the Xeloda market during the forecast period. Vascular disease affects the blood vessels that carry oxygen and nutrients throughout your body. Vascular problems happen because plaque which is made of fat and cholesterol blocks blood flow inside your arteries or veins. Some common vascular diseases are abdominal aortic aneurysms, aortic dissection, arteriovenous malformations, and atherosclerosis. They are common and serious problems in the modern era. Hence, this will drive the global market growth at a significant rate.

Key Features of the Reports

  • The xeloda market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

Xeloda Market Segmentation

By Type
  • 500mg
  • 150mg
By Application
  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Other
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Frequently Asked Questions

The xeloda market is poised to grow at a significant CAGR of 5.7% from 2023 to 2029

The leading players in the Xeloda market are; Philips Healthcare, Cheplapharm Arzneimittel GmbH, ResMed, Medtronic, BD, Getinge, Drager, Smith’s Group, Hamilton Medical, GE Healthcare, Fisher and Paykel, and Air Liquide.

Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation, and the forecast presented from 2023 to 2029.

  • Philips Healthcare
  • Cheplapharm Arzneimittel GmbH
  • ResMed
  • Medtronic
  • BD
  • Getinge
  • Drager
  • Smith’s Group
  • Hamilton Medical
  • GE Healthcare
  • Fisher and Paykel

Adjacent Markets